J Korean Rheum Assoc.  2007 Dec;14(4):431-435.

A Case of Isoniazid Induced Systemic Lupus Erythematosus

• Oh SR
• Cho M
• Ryu HS
• Lee JH
• Cho HJ
• Choi MK
• Oh JM
• Ahn SH
• Song JH
• Lee MS

Abstract

Many drugs have been known to induce lupus-like syndrome, composing approximately 10% of all SLE cases. Isoniazid-induced lupus erythematosus affects either sex equally and the most common presenting feature is arthralgia or arthritis with anemia. Fever and pleuritis occur in approximately half of the cases, and pericarditis in approximately 30% of cases. We discribe a 28-year-old woman receiving antituberculous medications including isoniazid for one month. She was hospitalized with fever, arthralgia and newly developed pleural effusion The analysis of pleural fluid and serum revealed an elevated level of antinuclear antibody. We suspected of drug induced lupus and stopped isoniazid medication. After discontinuation of isoniazid and short course of prednisolone treatment, her symptoms and pleural effusion disappeared. This case is to our knowledge, the fist report of isoniazid induced SLE in Korea.

Keyword

Systemic lupus erythematosus; Isoniazid; Drug

MeSH Terms

Adult
Anemia
Antibodies, Antinuclear
Arthralgia
Arthritis
Female
Fever
Humans
Isoniazid*
Korea
Lupus Erythematosus, Systemic*
Pericarditis
Pleural Effusion
Pleurisy
Prednisolone
Antibodies, Antinuclear
Isoniazid
Prednisolone

Figure

• 

  Fig. 1. Chest CT finding shows peribronchial distributed centrilobular nodules and tree in bud appearance in both upper lobes and lower lobe superior segment.

• 

  Fig. 2. Chest X-ray showed multiple nodular opacity and fibrosteaky opacity on both upper lung field with cavitary lesion. Large amount of pleural effusion was seen in right side.

• 

  Fig. 3. Chest X-ray showed improved lesion of both upper lung fields and disappeared previous right side pleural effusion.

Reference

1). Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syphilis. 1945. 51:190–2.

2). Lee SL., CHase PH. Drug-induced systemic lupus erythematosus: a critical review. Semin Arthritis Rheum. 1975. 5:83–103.

3). Weinstein A. Drug-induced systemic lupus erythematosus. Prog Clin Immunol. 1980. 4:1–21.

4). Rothfield NF., Bierer WF., Garfield JW. Isoniazid induction of antinuclear antibodies. A prospective study. Ann Intern Med. 1978. 88:650–2.

5). Atzeni F., Marrazza MG., Sarzi-Puttini P., Carrabba M. Drug-induced lupus erythematosus. Reumatismo. 2003. 55:147–54.

6). Antonov D., Kazandjieva J., Etugov D., Gospodinov D., Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol. 2004. 22:157–66.

7). Hess E. Drug-related lupus. N Engl J Med. 1988. 318:1460–2.

8). Yung RL., Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994. 20:61–86.

9). Siddiqui MA., Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther. 2002. 9:163–5.

10). Kang MJ., Lee YH., Lee JS. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006. 21:946–9.

11). Mario SP., Robert L., Ignacio G. Systemic lupus erythematosus induced by isoniazid. Ann Rheum Dis. 1992. 51:1085–7.

12). Rider V., Abdou NI. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int Immunopharmacol. 2001. 1:1009–24.

13). Jiang X., Khursigara G., Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science. 1994. 266:810–3.

14). Fazano CS., Bertin P. The pharmacological management of drug-induced rheumatic disorders. Expert Opin Pharmacother. 2001. 10:1623–31.